Teresa Foy

Teresa Foy

Director/Board Member at NANOSTRING TECHNOLOGIES, INC.

Net worth: 14 164 $ as of 2024-04-29

60 year
Health Technology
Consumer Services

Profile

Teresa M.
Foy
is an Independent Director at NanoString Technologies, Inc. and Senior VP-Immuno Oncology & Cell Therapy at Bristol Myers Squibb Co. She previously worked as Director-Preclinical Biology at Corixa Corp., Director-Preclinical Development at GlaxoSmithKline Biologicals NV, and Chief Scientific Officer at Oncofactor Corp.
She was also Senior Vice President-Research & Development at Viral Logic Systems Technology Corp.
from 2010 to 2012.
Foy holds a graduate degree from St. Cloud State University, a doctorate from the University of Iowa, and an undergraduate degree from the University of Minnesota.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2024-05-05 55,091 ( 0.11% ) 14 164 $ 2024-04-29

Teresa Foy active positions

CompaniesPositionStart
NANOSTRING TECHNOLOGIES, INC. Director/Board Member 2022-04-17
BRISTOL-MYERS SQUIBB COMPANY Corporate Officer/Principal 2019-10-31
All active positions of Teresa Foy

Former positions of Teresa Foy

CompaniesPositionEnd
Chief Tech/Sci/R&D Officer -
Corporate Officer/Principal -
Corporate Officer/Principal -
Chief Tech/Sci/R&D Officer -
See the detail of Teresa Foy's experience

Training of Teresa Foy

University of Minnesota Undergraduate Degree
University of Iowa Doctorate Degree
St. Cloud State University Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Teresa Foy's experience

Connections

96

1st degree connections

9

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies2
NANOSTRING TECHNOLOGIES, INC.

Health Technology

BRISTOL-MYERS SQUIBB COMPANY

Health Technology

Private companies4

Health Technology

Health Technology

Health Technology

Health Technology

See company connections
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW